AHA survey: Drug companies reduce access to care by limiting 340B community pharmacies

Nov 14, 2022 - 02:50 PM
340B pic

The AHA today released a new report showing how the unlawful actions of drug companies to limit 340B pricing with community and specialty pharmacies are having an adverse impact on access to care for patients and communities across the country. The report is based on a survey of more than 300 hospitals and health systems participating in the 340B program conducted earlier this year by the AHA.

Federally authorized arrangements between 340B hospitals and community and specialty pharmacies are a critical component of the 340B program that allow providers to expand access to many drugs — including those used to treat rare and complex conditions such as some cancers — for the patients and communities they serve.

According to the study:

  • The average 340B critical access hospital reported annualized losses of approximately $507,000, and the average disproportionate share hospital reported annualized losses of nearly $3 million.
  • On average, CAHs reported 44% of their total 340B savings coming from community and specialty pharmacies, with several CAHs reporting that their entire 340B savings come from these arrangements.
  • Overall, 10% of responding hospitals reported average annualized losses of $10 million or more, illustrating the magnitude of the harm that drug companies’ actions have on 340B hospitals and their ability to care for their patients.

“This important new report shows how unlawful actions by drug companies to restrict 340B discounts to community and specialty pharmacies are directly reducing access to care and services for patients and communities, especially those in rural areas,” said AHA Executive Vice President Stacey Hughes. “Drug companies are limiting discounts that help hospitals provide free care for uninsured patients, services in mental health clinics and many community health programs. To protect access to care, we continue to urge the Department of Health and Human Services to aggressively use all tools available to stop these harmful tactics from drug companies.”

Related News Articles

Headline
AHA submits comments on CMS draft guidance for Medicare drug price negotiation program
In a letter submitted July 2 to the Centers for Medicare & Medicaid Services on guidance for the Medicare Drug Price Negotiation Program, the AHA expressed…
Headline
Mississippi judge denies drug maker’s and PhRMA’s request for preliminary injunction in 340B case
A Mississippi judge July 1 denied Novartis Pharmaceuticals’ and PhRMA’s request for a preliminary injunction against enforcement of state law protecting 340B…
Headline
AHA, others file amicus brief in Maryland to prevent injunction against 340B pricing for contract pharmacy arrangements 
The AHA, 340B Health, the Maryland Hospital Association and the Mid-Atlantic Association of Community Health Centers June 26 filed an amicus brief in a federal…
Headline
AHA files amicus brief defending Mississippi law to protect 340B pricing for contract pharmacies 
The AHA, along with 340B Health, the Mississippi Hospital Association and the Rural Hospital Alliance filed an amicus brief June 18  in the U.S. District…
Headline
AHA submits comments on draft drug shortage legislation to Senate Finance Committee leaders 
The AHA June 7 submitted comments on a discussion draft of the Drug Shortage Prevention and Mitigation Act, bipartisan legislation proposing to provide…
Headline
House Energy and Commerce subcommittee holds 340B oversight hearing
The House Energy and Commerce Oversight and Investigations subcommittee June 4 hosted a hearing to discuss oversight of the 340B Drug Pricing Program. AHA sent…